Determinants of early and late mortality among HIV-infected individuals receiving home-based antiretroviral therapy in rural Uganda

Journal of Acquired Immune Deficiency Syndromes

Volumn 58, Issue 3, 2011, Pages 289-296

  Moore, David M ^a,b,c   Yiannoutsos, Constantin T ^d   Musick, Beverly S ^d   Tappero, Jordan ^a   Degerman, Richard ^a   Campbell, James ^e   Were, Willy ^a   Kaharuza, Frank ^a   Alexander, Lorraine N ^a   Downing, Robert ^a   Mermin, Jonathan ^a,f  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e US CDC   (Uganda)

^f Centers for Disease Control and Prevention Kenya   (Kenya)

Author keywords

Africa; anemia; antiretroviral therapy; mortality; tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT; HEMOGLOBIN;

ADULT; ARTICLE; BODY MASS; CD4 LYMPHOCYTE COUNT; CRYPTOCOCCOSIS; ESOPHAGUS CANDIDIASIS; FEMALE; FOLLOW UP; HEALTH PROGRAM; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; SURVIVAL; THRUSH; TUBERCULOSIS; UGANDA;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; RURAL POPULATION; SURVIVAL ANALYSIS; UGANDA; YOUNG ADULT;

EID: 80054887717     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182303716     Document Type: Article

References (30)

1. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS. 2004;18:887-895. (Pubitemid 38553709)
2. Ferradini L, Jeannin A, Pinoges L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet. 2006;367:1335-1342.
3. Laurent C, Diakhate N, Gueye NF, et al. The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS. 2002;16:1363-1370. (Pubitemid 34722068)
4. Wools-Kaloustian K, Kimaiyo S, Diero L, et al. Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. AIDS. 2006;20:41-48. (Pubitemid 41818113)
5. Munderi P, Watera C, Nakiyingi J, et al. Survival and causes of death, 2 years after introduction of Antiretroviral Therapy in Africa: a historical cohort comparison in Entebbe, Uganda. Presented at: 16th International AIDS Conference; August 13-18, 2006; Toronto, Canada.
6. Wester CW, Kim S, Bussmann H, et al. Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr. 2005;40: 336-343. (Pubitemid 41533075)
7. Marazzi MC, Liotta G, Germano P, et al. Excessive early mortality in the first year of treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited settings. AIDS Res Hum Retroviruses. 2008;24:555-560. (Pubitemid 351571039)
8. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001;286:2568-2577. (Pubitemid 33096808)
9. Chene G, Sterne JA, May M, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet. 2003;362:679-686.
10. Attia A, Huet C, Anglaret X, et al. HIV-1-related morbidity in adults, Abidjan, Cote d'Ivoire: a nidus for bacterial diseases. J Acquir Immune Defic Syndr. 2001;28:478-486. (Pubitemid 34033201)
11. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367:817-824.
12. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA. 2006;296:782-793. (Pubitemid 44223102)
13. Etard JF, Ndiaye I, Thierry-Mieg M, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS. 2006;20:1181-1189. (Pubitemid 43786107)
14. Lawn SD, Myer L, Harling G, et al. Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis. 2006; 43:770-776. (Pubitemid 44330743)
15. Lawn SD, Myer L, Orrell C, et al. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS. 2005;19:2141-2148. (Pubitemid 41669003)
16. Mermin J, Lule J, Ekwaru JP, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet. 2004;364:1428-1434. (Pubitemid 39370718)
17. Coutinho A, Mermin J, Ekwaru J, et al. Utility of routine viral load, CD4 cell count, and clinical monitoring among HIV-infected adults in Uganda: a randomized trial. Presented at: 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, MA.
18. Liechty CA, Solberg P, Were W, et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health. 2007;12:929-935. (Pubitemid 47245826)
19. Noura AA, Read KLQ. Proportional hazards changepoint models in survival analysis. Appl Stat. 1990;39:241-253.
20. Yiannoutsos CT. Modeling AIDS survival after initiation of antiretroviral treatment byWeibull models with changepoints. J Int AIDS Soc. 2009;12:9.
21. Weidle PJ, Wamai N, Solberg P, et al. Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet. 2006;368:1587-1594. (Pubitemid 44767594)
22. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: Recommendations towards a public health approach. Geneva, Switzerland: World Health Organization; 2010.
23. Uganda Ministry of Health. National antiretroviral treatment and care guidelines for adults, adolescents and children. 2nd ed. Katabira E, Kamya M, Kalyesubula I, editors Kampala, Uganda: Ministry of Health; 2008.
24. Bucher HC, Griffith LE, Guyatt GH, et al. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS. 1999;13:501-507.
25. Golub JE, Saraceni V, Cavalcante SC, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIVinfected patients in Rio de Janeiro, Brazil. AIDS. 2007;21:1441-1448. (Pubitemid 46988004)
26. Havlir DV, Dube MP, McCutchan JA, et al. Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS. Clin Infect Dis. 1998;27:1369-1375. (Pubitemid 29242405)
27. Chetchotisakd P, Sungkanuparph S, Thinkhamrop B, et al. A multicentre, randomized, double-blind, placebo-controlled trial of primary cryptococcal meningitis prophylaxis in HIV-infected patients with severe immune deficiency. HIV Med. 2004;5:140-143. (Pubitemid 38765279)
28. Muller M, Wandel S, Colebunders R, et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 10: 251-261.
29. Murdoch DM, Venter WD, Feldman C, et al. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS. 2008;22:601-610. (Pubitemid 351640593)
30. Castelnuovo B, Manabe YC, Kiragga A, et al. Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort. Clin Infect Dis. 2009;49:965-972.